CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Kazama, Hiromi [2 ]
Moriya, Shota [2 ]
Takano, Naoharu [2 ]
Hiramoto, Masaki [2 ]
Miyazawa, Keisuke [2 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morpho, Sch Med, Tokyo, Japan
[2] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PJ16-4-3
引用
收藏
页码：900 / 900
页数：1
相关论文
共 50 条
  • [1] Molecular mechanism of vacuolar formation associated with cell death induced by CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Tanaka, Yoshinori
    Okimoto, Tomoya
    Ikeda, Toshikatsu
    Hara, Tomoyo
    Takeya, Kosuke
    Takano, Naoharu
    Hiramoto, Masaka
    Aizawa, Shin
    Miyazawa, Keisuke
    Eto, Masumi
    Hirai, Shuichi
    CANCER SCIENCE, 2025, 116 : 1741 - 1741
  • [2] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [3] Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
    Eskiler, Gamze Guney
    Ozkan, Asuman Deveci
    Haciefendi, Ayten
    Bilir, Cemil
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [4] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [5] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [6] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [7] Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells
    Abutorabi, Elaheh Seyed
    Irani, Shiva
    Yaghmaie, Marjan
    Ghaffari, Seyed Hamid
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2020, 8 (04): : 438 - 445
  • [8] Lysosome-targeted cytocidal effect of CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2018, 109 : 1026 - 1026
  • [9] Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
    Liang, Muh-Lii
    Chen, Chun-Han
    Liu, Yun-Ru
    Huang, Man-Hsu
    Lin, Yu-Chen
    Wong, Tai-Tong
    Lin, Sey-En
    Chu, Shing-Shiung
    Ding, Yi-Huei
    Hsieh, Tsung-Han
    CANCERS, 2020, 12 (12) : 1 - 17
  • [10] A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
    Chong, Qing-Yun
    Kok, Ze-Hui
    Bui, Ngoc-Linh-Chi
    Xiang, Xiaoqiang
    Wong, Andrea Li-Ann
    Yong, Wei-Peng
    Sethi, Gautam
    Lobie, Peter E.
    Wang, Lingzhi
    Goh, Boon-Cher
    PHARMACOLOGICAL RESEARCH, 2020, 156
12345